01 / DESIGN
What was studied?
A randomized phase 3 trial compared mazdutide with a specified dulaglutide regimen in adults receiving background oral diabetes medicines.
02 / FINDINGS
What did the researchers report?
Mazdutide met the trial's non-inferiority and superiority criteria for glycated-hemoglobin change, with greater weight reductions. Gastrointestinal events were more common.
03 / LIMITS
How should it be interpreted?
The comparison is against the particular comparator regimen tested. It cannot rank every available treatment or establish equivalence between the trial product and supplier materials.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.